Stockscreener 앱 받기
3.49
1.16%
0.04
전일 마감가:
$3.45
열려 있는:
$3.43
하루 거래량:
13,833
Relative Volume:
0.14
시가총액:
$31.78M
수익:
$170.00K
순이익/손실:
$-16.35M
주가수익비율:
-1.8758
EPS:
-1.8605
순현금흐름:
$-13.66M
1주 성능:
+0.87%
1개월 성능:
+10.09%
6개월 성능:
+70.24%
1년 성능:
+39.04%
1일 변동 폭
$3.43
$3.4999
1주일 범위
$3.40
$4.04
52주 변동 폭
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
3.49 | 31.42M | 170.00K | -16.35M | -13.66M | -1.8605 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA) - marketscreener.com
Lisata Therapeutics (LSTA) Rises 2.3% as Stock Tests Key ResistanceHigh Conviction Picks - newsline.com
LSTA Rallies 2.3% to $3.56 as Support Holds Ahead of ResistanceDip Buy Trade - newsline.com
LSTA Q3 2025 Earnings: EPS Beat Exceeds Expectations as Clinical Progress ContinuesQuarterly Financial Update - newsline.com
Lisata shares nearly double on buyout offer: Here are the details - MSN
Kuva Labs Agrees to Acquire Lisata Therapeutics for Four Dollars Per Share - HarianBasis.co
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share - Yahoo Finance
Kuva Labs launches $4/share tender offer to acquire Lisata Therapeutics, plus potential $3/share milestone payments. - Pluang
Lisata Therapeutics (NASDAQ: LSTA) to be acquired for $4.00 cash plus CVRs - Stock Titan
Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA) - Stock Titan
Press Release: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - Moomoo
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LSTA Q3 2025 Earnings: Narrower Loss Surpasses Estimates as Clinical Progress ContinuesCFO Commentary Report - newsline.com
Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp – Minichart - Minichart
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline - TipRanks
Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17 - TradingView
Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee - Stock Titan
LSTA Q3 2025 Earnings: EPS Surpasses Estimates Despite Lack of Revenue, Stock Edges LowerRetail Earnings Report - newsline.com
LSTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lisata Therapeutics (LSTA) Holds Steady at $3.37 as Key Levels NarrowPCR Spike - newsline.com
Lisata Therapeutics (LSTA) Eases Amid Modest Pullback — Key Support Levels in FocusMoving Average Crossovers - newsline.com
LSTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com UK
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer - TipRanks
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement - Minichart
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss Marks Progress in Clinical-Stage BiotechRevenue Growth Outlook - The Legal Advocate
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics - Kavout
Stocks to Watch: Oculis, Lisata, Healthy Choice Wellness - Moomoo
Lisata Therapeutics Revises Merger Terms, Adds Milestone CVRs - TipRanks
Lisata Therapeutics (LSTA) preliminary tender-offer communication; merger dated March 6, 2026 - Stock Titan
Lisata Therapeuticsamends merger offer price to $4 per share plus CVR - marketscreener.com
Lisata Agrees to $4 Cash Plus Up to $3 CVR in Amended Kuva Tender Offer - TradingView
Lisata (NASDAQ: LSTA) cuts cash to $4, lifts CVR upside to $3 - Stock Titan
LSTA Technical Analysis | Trend, Signals & Chart Patterns | LISATA THERAPEUTICS INC (NASDAQ:LSTA) - ChartMill
Lisata Therapeutics (LSTA) Q3 2025 Earnings: EPS Beat Drives Positive Stock ReactionSubscription Growth Report - The Legal Advocate
Lisata, Mobileye, VF, Canada Goose, F5 Trending With Analysts - TipRanks
Lisata Therapeutics (LSTA) Holds Steady at $3.14 as Range-Bound Trading PersistsLow Volume Node - The Legal Advocate
Lisata Therapeutics (LSTA) Delivers Q3 2025 Beat — EPS $-0.49 vs $-0.55 ExpectedFinancial Summary - Newser
H.C. Wainwright Maintains Lisata Therapeutics(LSTA.US) With Hold Rating - Moomoo
Lisata Therapeutics (LSTA) Climbs +2.92% — Resistance at $3.33 in Focus 2026-05-17Stock Analysis - Newser
LSTA Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
HC Wainwright Downgrades Lisata Therapeutics to Neutral From Buy - marketscreener.com
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral - Investing.com
H.C. Wainwright Downgrades Lisata Therapeutics(LSTA.US) to Hold Rating - Moomoo
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):